Influence of Prenatal Lead Exposure on Genomic Methylation of Cord Blood DNA by Pilsner, J. Richard et al.
1466  v o l u m e  117 | n u m b e r 9 | September 2009  •  Environmental Health Perspectives
Research | Children’s Health
As of 2006, an estimated ≥ 275,000 children 
in the United States continue to have blood 
lead levels exceeding the U.S. Centers for 
Disease Control and Prevention (CDC) limit 
of concern of 10 µg/dL (CDC 2006; Meyer 
et al. 2003). In developing countries, the 
prevalence of elevated blood lead levels greatly 
surpasses U.S. numbers and signifies a public 
health priority of global magnitude (Toscano 
and Guilarte 2005). Lead exposure produces 
a wide spectrum of health outcomes, most 
notably neurocognitive and behavioral deficits 
in response to pre- and/or postnatal exposures 
(Needleman et al. 1990). Lead exposure has 
also been associated with spontaneous abor-
tions (Borja-Aburto et al. 1999) and other 
adverse birth outcomes, such as preterm deliv-
eries (Andrews et al. 1994; Jelliffe-Pawlowski 
et al. 2006) and low birth weight (Bellinger 
et al. 1991; Gonzalez-Cossio et al. 1997), 
which are risk factors for adverse health out-
comes over the life course (Barker et al. 1989; 
Rich-Edwards et al. 1997). Recently, blood 
levels < 10 µg/dL during early childhood have 
been reported to confer reductions in IQ 
scores (Canfield et al. 2003; Lanphear et al. 
2005), further questioning whether a thresh-
old exists for the adverse consequences of lead 
exposure. Despite the well-documented clini-
cal manifestations of lead toxicity, the bio-
logical mechanisms underlying these adverse 
health effects are poorly characterized.
Lead has long been known to readily dif-
fuse across the placenta (Barltrop 1968; Goyer 
1990) and therefore represents a significant 
mode of exposure to the developing fetus. 
Pregnancy and lactation are also associated 
with a marked increase in maternal bone turn-
over (Sowers et al. 1993). Consequently, it is 
now appreciated that prenatal lead exposure 
can occur not only through current maternal 
environmental exposures, but also through 
the mobilization of cumulative maternal bone 
lead stores during pregnancy and lactation 
(Gulson et al. 1997, 2003; Tellez-Rojo et al. 
2002). Thus, bone lead stores represent an 
environmental threat not only for women 
with current exposure, but also for women 
with elevated lead exposures in the past.
Epidemiologic and experimental studies 
strongly suggest that environmental events 
during fetal development produce persistent 
effects on cellular function, which in turn 
may influence the trajectory of health events 
throughout the life course (Barker et al. 1989; 
Godfrey and Barker 2001). A likely target by 
which early-life environmental events dictate 
disease susceptibility is through epigenetic 
programming. The epigenome is likely highly 
vulnerable to environmental factors during 
embryogenesis because of the extensive epi-
genetic reprogramming that occurs shortly 
after fertilization. In addition, the high rate 
of mitosis presents an opening during which 
the elaborate nature of the DNA methyla-
tion and chromatin patterning required for 
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Ba c k g r o u n d: Fetal lead exposure is associated with adverse pregnancy outcomes and developmen-
tal and cognitive deficits; however, the mechanism(s) by which lead-induced toxicity occurs remains 
unknown. Epigenetic fetal programming via DNA methylation may provide a pathway by which 
environmental lead exposure can influence disease susceptibility.
oB j e c t i v e: This study was designed to determine whether prenatal lead exposure is associated with 
alterations in genomic methylation of leukocyte DNA levels from umbilical cord samples.
Me t h o d s : We measured genomic DNA methylation, as assessed by Alu and LINE-1 (long 
interspersed nuclear element-1) methylation via pyrosequencing, on 103 umbilical cord blood 
samples from the biorepository of the Early Life Exposures in Mexico to Environmental Toxicants 
(ELEMENT) study group. Prenatal lead exposure had been assessed by measuring maternal bone 
lead levels at the mid-tibial shaft and the patella using a spot-source 109Cd K-shell X-ray fluores-
cence instrument.
re s u l t s: We found an inverse dose–response relationship in which quartiles of patella lead cor-
related with cord LINE-1 methylation (p for trend = 0.01) and and tibia lead correlated with Alu 
methylation (p for trend = 0.05). In mixed effects regression models, maternal tibia lead was nega-
tively associated with umbilical cord genomic DNA methylation of Alu (β = –0.027; p = 0.01). We 
found no associations between cord blood lead and cord genomic DNA methylation.
co n c l u s i o n s: Prenatal lead exposure is inversely associated with genomic DNA methylation in 
cord blood. These data suggest that the epigenome of the developing fetus can be influenced by 
maternal cumulative lead burden, which may influence long-term epigenetic programming and dis-
ease susceptibility throughout the life course.
key w o r d s : blood lead, bone lead, DNA methylation, early life, epigenetics, fetal programming, 
genomic DNA methylation, intergenerational, lead exposure, life course, Mexico. Environ Health 
Perspect 117:1466–1471 (2009).  doi:10.1289/ehp.0800497 available via http://dx.doi.org/ [Online 
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normal tissue development is susceptible 
to environmental influence (Dolinoy et al. 
2007b). DNA methylation is the most widely 
studied of the known epigenetic marks and 
plays important roles in transcriptional regu-
lation, X chromosome inactivation, embry-
onic development, imprinting, suppression of 
parasitic DNA sequences, and maintenance 
of genomic stability (Li et al. 1993). In ani-
mal models, maternal dietary supplementa-
tion (Dolinoy et al. 2006; Waterland and 
Jirtle 2003) and chemical exposures (Anway 
et al. 2006; Chang et al. 2006; Dolinoy et al. 
2007a) have been shown to modulate DNA 
methylation patterns that were stable among 
unexposed groups. To date, no data exist 
regarding the influence of in utero environ-
mental lead exposure on DNA methylation 
levels in humans.
We conducted a cross-sectional study to 
determine whether biological markers of pre-
natal maternal lead exposure are associated 
with genomic methylation of leukocyte DNA 
in umbilical cord samples from a birth cohort 
in Mexico City.
Materials and Methods
Sample population. The Early Life Exposures 
in Mexico to Environmental Toxicants 
(ELEMENT) study is a group of sequentially 
enrolled epidemiologic birth cohort studies 
with the aim of investigating the influence 
of cumulative maternal lead burden on fetal 
and infant development. For the present 
study, which uses data and biological sam-
ples from the first birth cohort, maternal–
infant pairs were recruited between 1994 and 
1995 from three hospitals in Mexico City 
(Mexican Social Security Institute, Manuel 
Gea Gonzalez Hospital, and National 
Institute of Perinatology), which serve low- 
to moderate-income populations. Exclusion 
criteria included factors that could interfere 
with maternal calcium metabolism; medical 
conditions that could cause low birth weight 
(< 2,000 g); logistic reasons that would inter-
fere with data collection (households living 
outside the metropolitan area); delivering a 
premature neonate (< 37 weeks) or an infant 
with an Apgar score at 5 min of ≤ 6; con-
ditions requiring placement in a neonatal 
intensive care unit; a physician’s diagnosis 
of multiple fetuses; intention not to breast-
feed; preeclampsia; psychiatric, kidney, or 
cardiac diseases; gestational diabetes; his-
tory of repeated urinary infections; family or 
personal history of kidney stone formation; 
seizure disorder requiring daily medication; 
ingestion of corticosteroids; or blood pres-
sure > 140 mmHg systolic or > 90 mmHg 
diastolic. Of the initial 1,382 mothers who 
remained eligible, 617 agreed to participate 
and continued in the birth cohort study. 
Of these, 412 umbilical cord samples had 
DNA extracted. For this study, we selected 
only those samples that had > 10 µg of DNA 
available to analyze for this initial study of 
genomic DNA methylation markers LINE-1 
(long interspersed nuclear elements-1) and 
Alu. Our final study population consisted of 
103 umbilical cord samples.
The study protocol was approved by the 
Ethics Committee of the National Institute 
of Public Health of Mexico, the participat-
ing hospitals, the Brigham and Women’s 
Hospital, the Harvard School of Public 
Health, and the University of Michigan. 
All participating mothers received a detailed 
explanation of the study intent, research pro-
cedures, and counseling on how to reduce 
environmental lead exposure.
Blood lead measurements. Umbilical cord 
venous blood samples were collected in trace 
metal–free tubes at delivery. Blood samples 
were analyzed using an atomic absorption 
spectrometry instrument (model 3000; 
PerkinElmer, Chelmsford, MA, USA) at the 
metals laboratory of the American British 
Cowdray Hospital in Mexico City. External 
blinded quality-control samples were provided 
throughout the study period by the Maternal 
and Child Health Bureau and the Wisconsin 
State Laboratory of Hygiene Cooperative 
Blood Lead Proficiency Testing Program. 
Bone lead measurements. Maternal bone 
lead was measured noninvasively around 1 
month postpartum using a spot-source 109Cd 
K-shell X-ray fluorescence (K-XRF) instru-
ment constructed at Harvard University and 
installed in a research facility in the American 
British Cowdray Medical Center. The physi-
cal principles, technical specifications, and 
validation of this and other similar K-XRF 
instruments have been described in detail 
elsewhere (Aro et al. 1994). For this study, 
30-min measurements were taken at the 
mid-shaft of the left tibia (cortical bone) and 
the left patella (trabecular bone). Analysis of 
means and standard deviations of phantom-
calibrated measurements did not disclose any 
significant shift in accuracy or precision. As 
a quality control measure, we excluded any 
tibia lead measurements with an uncertainty 
> 10 µg/g or any patella lead measurements 
with an uncertainty > 15 µg/g.
DNA extraction and bisulfite conver-
sion. DNA extraction was performed in the 
Harvard-Partners Center for Genetics and 
Genomics. We extracted high-molecular-
weight DNA with commercially available 
PureGene Kits (Gentra Systems, Minneapolis, 
MN, USA) from the white blood cells of 
archived umbilical cord blood samples that 
were collected at delivery. After transport to 
the Environmental Epigenetics Laboratory at 
the University of Michigan School of Public 
Health, DNA samples (200 ng at 10 ng/µL) 
were bisulfite-treated using the EZ-96 DNA 
Methylation-Gold Kit (Zymo Research, 
Orange, CA, USA). Bisulfite conversion 
of DNA changes unmethylated cytosine to 
uracil and subsequently to thymidine after 
polymerase chain reaction (PCR), whereas 
methylated cytosines are protected from 
bisulfite conversion, resulting in methylation-
dependent differences in DNA sequences. 
Bisulfite-converted DNA was stored at –20°C 
until further use.
Quantitation of LINE-1 and Alu 
methylation. We measured LINE-1 and 
Alu methylation by quantitative pyrose-
quencing using primers and conditions as 
described previously (Bollati et al. 2007; 
Choi et al. 2007). We performed the LINE-1 
assay using 10 pmol of forward primer 5´- 
TTTTGAGTTAGGTGTGGGATATA-3´ 
and 10 pmol of reverse biotinylated primer 
5´-AAAATCAAAAAATTCCCTTTC-3´ 
using the following running conditions: 
95°C for 14.5 min, then 35 cycles of 30 sec 
each at 95°C, 55°C, and 72°C, followed by 
72°C for 7 min. We performed the Alu assay 
using 10 pmol of forward biotinylated primer 
5´-TTTTTATTAAAAATATAAAAATT-3´ 
and 10 pmol of reverse primer 5´-CCCA-
AACTAAAATACAATAA-3´ using the fol-
lowing conditions: 95°C for 14.5 min, then 
40 cycles for 30 sec each at 95°C, 42°C, and 
72°C, followed by 72°C for 7 min. We per-
formed the Alu and LINE-1 assays in a 25-µL 
PCR using HotStarTaq Master Mix (Qiagen, 
Valencia, CA, USA). For sample controls, we 
used human genomic DNA that had under-
gone whole-genome amplification to remove 
CpG methylation and a human methylated 
standard (Zymo Research) as 0% and 100% 
methylated controls, respectively.
Pyrosequencing involves use of a primer 
extension reaction, using a biotin-labeled 
single-stranded PCR amplicon as template, 
in which pyrophosphatase is released dur-
ing the incorporation of each nucleotide in 
equimolar proportion to that incorporated. 
Incorporation of either T (for unmethy-
lated cytosine) or C (for methylated cyto-
sine) at each CpG provides a quantitative 
meas    ure for consecutive CpG sites through-
out the region sequenced. We used the 
  biotin-labeled primer to purify the final PCR 
product using streptavidin Sepharose High 
Performance beads (Amersham Biosciences, 
Uppsala, Sweden). Sepharose beads bound 
to the PCR product were purified, dena-
tured, and washed using the Pyrosequencing 
Vacuum Prep Tool (Qiagen, Valencia, 
CA, USA). We annealed pyrosequencing 
primers (0.3 µmol/L) to the purified PCR 
product and sequenced them on a PSQ 
HS96 Pyrosequencing System (Qiagen). 
Sequencing primers for Alu and LINE-1 
were 5´-AATAACTAAAATTACAAAC 
and 5´-AGTTAGGTGTGGGATATAGT, Pilsner et al.
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respectively. We quantified the level of meth-
ylation for each CpG target region using the 
Pyro Q-CpG Software (Qiagen). This soft-
ware assigns quality scores for each measure-
ment and internal quality controls to assess 
the efficiency of bisulfite conversion.
Statistical analyses. We analyzed data 
using SAS (version 9.1; SAS Institute Inc., 
Cary, NC, USA) and R 2.6.1 (R Foundation 
for Statistical Computing, Vienna, Austria). 
We examined descriptive statistics and 
identification of outliers using the general-
ized extreme studentized deviation method 
(Rosner 1983) for all variables. All cord blood 
lead measures were loge-transformed before 
statistical analysis. For both LINE-1 and Alu, 
we averaged the DNA methylation measures 
across CpG cites within individuals and used 
the individual averages to construct descrip-
tive statistics of the study sample.
We used mixed-effects regression models 
to describe the relationships between infant 
DNA methylation measures of LINE-1 and 
Alu and biomarkers of lead exposure with 
and without adjusting for covariates of inter-
est. We used mixed-effects models because 
three (Alu) or four (LINE-1) measures (at 
each CpG dinucleotide site) are available per 
individual. The basic model employed was 
yij = β0 + β1 lead.measurei + bj + εij, where i 
indexes the individual, and j = 1,2,3 (or j = 
1,2,3,4) indexes CpG site. In the model, β0 
represents the population average methyla-
tion percentage across CpG sites, whereas the 
random effect bj captures departures from the 
overall mean for each CpG site. The random 
errors εij values capture individual variabil-
ity at each CpG site and may be correlated 
within individuals. We considered two cova-
riance structures to model the correlation of 
observations within individuals: an unstruc-
tured covariance and a compound symmetry 
structure (which is equivalent to modeling an 
individual-level random intercept). We used 
likelihood ratio tests to choose the correlation 
structure for the error term εij; for both Alu 
and LINE-1 the unstructured correlation had 
significantly better fit (p < 0.001).
We estimated models for each marker of 
lead exposure as well as for bone lead meas-
ures adjusting for blood lead concentrations. 
We treated the lead exposure measures as 
continuous variables, as a set of indicator vari-
ables to represent exposure quartiles, or as 
ordinal variables representing quartiles for 
tests of trend. We chose the potential con-
founding variables considered in our model 
based on biologic plausibility or those sig-
nificantly associated with DNA methylation 
markers or lead exposures (p < 0.1: LINE-1 
and maternal age, β = –0.09 ± 0.05; tibia lead 
and infant sex, β = –2.92 ± 1.72) in bivariate 
analysis; variables included were maternal age 
at delivery (years), maternal education (years), 
cigarette smoking during pregnancy (yes/no), 
and infant sex (male sex as reference group). 
We also investigated the adjusted relationships 
between quartiles of lead exposures and DNA 
methylation levels and used the estimates to 
construct a graphical representation of the 
association. We performed regression diagnos-
tics on all models to evaluate multi  collinearity 
and violations of the linear regression model 
assumptions.
Results
Table 1 provides demographic and biological 
characteristics among newborns according to 
their participation status in the present study 
from the ELEMENT study. We found no sig-
nificant differences in mean lead exposures, 
newborn sex, maternal age, education, smok-
ing status, or body mass index by participation 
status. Among umbilical cord samples, eight 
(7.8%) had blood lead concentrations > 10 µg/
dL. Table 2 shows the unadjusted associations 
between quartiles of lead exposures and Alu 
and LINE-1 methylation. The average methy-
lation of Alu repeats in newborns was 25.76% 
(range, 22.95–27.75%), whereas LINE-1 
methylation was 79.48% (74.15–84.94%). 
Quartiles of maternal tibia lead levels were 
inversely associated with Alu methylation in 
newborn samples (p for trend = 0.04), whereas 
quartiles of maternal patella lead measures were 
inversely associated with LINE-1 methylation 
in newborn samples (p for trend = 0.007). 
Moreover, compared with the first quartile, 
the fourth quartile for maternal patella lead 
was associated with significantly lower LINE-1 
methylation levels in cord samples (β = –1.34, 
p = 0.01). We found no significant associations 
between cord blood lead measures and Alu or 
LINE-1 methylation.
Table 3 shows the results from the models 
adjusting for possible confounding factors such 
as maternal age, education, smoking status 
during pregnancy, and newborn sex. Mixed 
models with controlling for cord blood lead 
revealed a modest inverse relationship between 
maternal patella lead and LINE-1 methylation 
(β = –0.025, p = 0.08). We also observed an 
inverse association between maternal tibia lead 
and Alu methylation levels with and without 
controlling for cord blood (β = –0.027, p = 
0.009, and β = –0.027, p = 0.01, respectively). 
Again, cord blood lead was not significantly 
associated with DNA methylation.
Figure 1 illustrates the relationship 
between quartiles of cumulative lead measures 
and mean Alu and LINE-1 methylation levels 
in cord samples after controlling for maternal 
age, education, smoking during pregnancy, 
and child sex. An inverse dose–response 
Table 1. Characteristics [mean ± SD or no. (%)] of newborns by participation status.
Measure
Nonparticipating newborns 
(n = 528)
Participating newborns 
(n = 103) p-Value
Maternal tibia lead (µg/g) 9.9 ± 10.4 (n = 515) 10.5 ± 8.4 (n = 102) 0.27
Maternal patella lead (µg/g) 15.3 ± 15.7 (n = 489) 12.9 ± 14.3 (n = 100) 0.20
Cord blood lead (µg/dL) 6.6 ± 3.8 (n = 417) 6.6 ± 2.7 (n = 103) 0.32
Maternal body mass index (kg/m2) 23.5 ± 3.4 (n = 416) 23.8 ± 4.9 (n = 80) 0.61
Maternal age (years) 24.5 ± 5.2 24.4 ± 4.8 0.90
Maternal education (years school) 9.2 ± 4.8 9.5 ± 3.6 0.24
Newborn sex (male) 287 (54.9) 55 (52.9) 0.81
Smoking during pregnancy 24 (4.6) 3 (2.9) 0.45
Table 2. Unadjusted Alu and LINE-1 methylation of cord blood (%) by quartiles of lead exposures.
Variable  No. Alu ± SD LINE-1 ± SD
Overall mean 103 25.76 ± 1.04 79.48 ± 2.18
Maternal tibia lead (µg/g)
  ≤ 4.8 25 26.00 ± 0.94 79.72 ± 2.16
  > 4.8 and ≤ 9.7 26 25.78 ± 0.84 79.31 ± 2.53
  > 9.7 and ≤ 16.4 26 25.75 ± 1.07 79.55 ± 2.01
  > 16.4 25 25.71 ± 1.07 79.37 ± 2.11
  p-Value for trenda 0.04 0.38
Maternal patella lead (µg/g)
  ≤ 2.2 25 25.65 ± 0.75 80.08 ± 2.33
  > 2.2 and ≤ 12.1  25 26.18 ± 1.06 79.78 ± 1.68
  > 12.1 and ≤ 21.8 25 25.84 ± 0.99 79.25 ± 1.91
  > 21.8 25 25.52 ± 1.02 78.57 ± 2.48
  p-Value for trenda 0.10 0.007
Cord blood lead (µg/dL)
  ≤ 4.4 25 25.68 ± 1.00 79.17 ± 2.09
  > 4.4 and ≤ 6.2 27 25.73 ± 1.13 79.37 ± 1.99
  > 6.2 and ≤ 7.9 26 25.99 ± 0.77 79.84 ± 2.13
  > 7.9 25 25.79 ± 1.00 79.55 ± 2.55
  p-Value for trenda 0.33 0.46
aObtained using mixed-effects models.Prenatal lead exposure and DNA methylation
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relationship between patella lead and LINE-1 
methylation in cord samples remained sig-
nificant (p for trend = 0.01). Furthermore, 
quartiles of maternal tibia lead displayed a 
dose-dependent pattern with Alu methylation 
in cord samples (p for trend = 0.05).
Discussion
There is increasing epidemiologic and experi-
mental evidence that early-life environmental 
events affect health outcomes (Barker et al. 
1989; Godfrey and Barker 2001). This “fetal 
origins of disease” hypothesis suggests that 
environmental factors during development pro-
gram genetic expression profiles in such a man-
ner that influences the susceptibility to chronic 
diseases throughout the life course. Unlike the 
static nature of DNA, the epigenome is rela-
tively dynamic and provides a suitable pathway 
by which environmental factors can influence 
disease susceptibility. Although epigenetics 
have been the center of intense investigation in 
cancer research, epigenetics has been minimally 
applied to understand early life events and the 
impact of environmental risk factors on such 
events in human populations.
In mammals, DNA methylation almost 
exclusively occurs within CpG dinucleotides, 
where an estimated 70% of all CpG dinucleo-
tides are methylated (Robertson and Wolffe 
2000). There are two distinct, but seemingly 
opposing, changes in the epigenome dur-
ing disease: gene-specific hypermethylation, 
which is associated with gene repression, and 
an overall decrease in 5-methyl cytosine con-
tent, referred to as genomic hypomethylation. 
DNA methylation levels in LINE-1 and Alu 
elements have been routinely used as a sur-
rogate measure of genomic DNA methylation 
levels (Choi et al. 2007; Perrin et al. 2007; 
Yang et al. 2004). It is estimated that 0.5 and 
1.5 million copies of LINE-1 and Alu exist in 
the human genome, respectively, and together 
they comprise around 25% of the genome 
and > 40% of methylated CpG domains 
(Choi et al. 2007; Rollins et al. 2006). DNA 
methylation within these repetitive elements 
are thought to play a critical role in genomic 
defense and structural integrity by silenc-
ing expression of these transposon elements, 
thereby limiting chromosomal rearrangement 
and translocation events (Wilson et al. 2007).
In this study, we examined the asso-
ciations between maternal lead burden and 
genomic DNA methylation levels in umbili-
cal cord blood samples. Our most prominent 
findings were those investigating the impact 
of maternal cumulative bone lead measures 
on genomic DNA methylation. In mixed-
effects models, maternal tibia and patella lead 
measures were inversely associated with Alu 
and LINE-1 methylation levels, respectively. 
We found no associations between cord blood 
lead and DNA methylation.
This study, to our knowledge, is the 
first to examine the effect of maternal lead 
burden on genomic DNA methylation lev-
els from cord blood samples in humans. 
Environmental exposures can influence early- 
life events through two distinct processes, epi-
genetic fetal programming and transgenera-
tional epigenetic inheritance. Epigenetic fetal 
programming is limited to modifications of 
the epigenome of the developing offspring, 
primarily targeting somatic cells that are 
responsible for tissue-specific gene expres-
sion. Alternatively, environmental factors can 
induce the transgenerational inheritance of 
phenotype through germline alterations in 
the epigenome; however, to be considered 
a transgenerational effect, these epigenetic 
changes must persist through the F3 gen-
eration (Jirtle and Skinner 2007). Previous 
research using animal models has highlighted 
the importance of early-life environment 
events in programming DNA methylation 
patterns, which in turn alters disease suscepti-
bility throughout the life course. In the agouti 
mouse model, maternal dietary supplementa-
tion, such as methyl-donor groups (Waterland 
and Jirtle 2003) and genistein (Dolinoy et al. 
2006), and maternal bisphenol-A exposure 
(Dolinoy et al. 2007a) have been shown to 
alter phenotype and predisposition of off-
spring to adult-onset obesity and cancers 
through alterations in DNA methylation 
during early development. Moreover, brief 
in utero exposure to arsenic has been reported 
to alter DNA methyl  ation in GC-rich regions 
among offspring (Xie et al. 2007), produc-
ing multiple tissue-specific tumors when the 
offspring reached adulthood (Waalkes et al. 
2003, 2004). Emerging data also suggest that 
in utero exposures to environmental toxi-
cants can elicit epigenetic transgenerational 
inheritance over multiple generations through 
effects on the germline (Anway et al. 2006; 
Chang et al. 2006; Jirtle and Skinner 2007).
Of particular relevance to the impact of 
lead on fetal origins of disease has been novel 
work by Zawia and colleagues using rodent 
and monkey models (Basha et al. 2005; Wu 
et al. 2008) to demonstrate that early-life 
lead exposure can predetermine the late-life 
expression and regulation of the amyloid pre-
cursor protein as well as a decrease in DNA 
methyltransferase activity. These results sug-
gest that epigenetic programming may be a 
mechanism by which lead alters susceptibility 
to diseases such as Alzheimer’s disease. Our 
findings also indicate that the epigenome of 
the developing fetus is influenced by mater-
nal cumulative lead burden. Taken together, 
these data suggest that early-life lead exposure 
may influence long-term epigenetic program-
ming, which in turn may affect susceptibility 
to disease throughout the life course.
Interestingly, in our study DNA methyla-
tion levels were associated only with cumula-
tive measures of bone lead and not with blood 
lead concentrations. Previous studies from our 
group have demonstrated that maternal bone 
lead is a better biomarker than either cord 
blood or postnatal blood lead for predicting 
Table 3. Mixed-effects regression models of cord blood DNA methylation, and lead biomarkers controlled 
for maternal age, maternal education, infant sex, and smoking status during pregnancy.
Mean infant DNA methylation (β ± SE)
Measure Alu LINE-1
Cord blood lead   0.176 ± 0.23   0.45 ± 0.49
Maternal tibia lead –0.027 ± 0.01** –0.002 ± 0.02
Maternal tibia leada –0.027 ± 0.01# –0.003 ± 0.02
Maternal patella lead –0.005 ± 0.01 –0.020 ± 0.01
Maternal patella leada –0.007 ± 0.01 –0.025 ± 0.01*
aModels also controlled for cord blood lead. *p < 0.10. **p < 0.05. #p < 0.01.
Figure 1. Differences (95% confidence intervals) in percent methylation of cord leukocyte DNA compar-
ing quartiles (Q) of maternal cumulative lead exposure obtained from mixed-effects regression models 
adjusting for maternal age, education, smoking status during pregnancy, and newborn sex using quartile 
1 as referent. (A) LINE-1 methylation of cord leukocyte DNA by maternal patella lead quartiles (p for 
trend = 0.01). (B) Alu methylation of cord leukocyte DNA by maternal tibia lead quartiles (p for trend = 0.05).
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adverse birth outcomes, such as birth weight 
(Gonzalez-Cossio et al. 1997), and neurode-
velopmental outcomes (Gomaa et al. 2002). 
Lead levels in blood serve as measures of cur-
rent biologically active lead and are considered 
a better marker of recent exposures. In con-
trast, bone lead acts both as a repository for 
cumulative lead exposure as well as a source 
of exposure itself upon normal bone turn-
over and thus is a better indicator of chronic 
exposure. Therefore, factors that influence 
bone turnover and thus bone lead mobiliza-
tion, such as pregnancy and lactation, may 
modify the toxicity of lead (Gulson et al. 
2003; Tellez-Rojo et al. 2002). Indeed, isoto-
pic speciation studies have demonstrated that 
the skeletal contribution to blood lead levels 
increases from 9% to 65% during pregnancy 
(Gulson et al. 1997).
The mechanism(s) involved in lead’s 
impact on genomic DNA methylation levels 
in cord samples are unclear. Chronic exposure 
of lead has been shown to increase the gen-
eration of reactive oxygen species (Adonaylo 
and Oteiza 1999; Antonio-Garcia and Masso-
Gonzalez 2008), which have been shown to 
inhibit binding of methyl-CpG binding pro-
teins and alter DNA methyltransferase func-
tion (Valinluck et al. 2004). We can only 
speculate that perhaps lead-induced oxidative 
stress may reduce the fidelity of the epigenetic 
machinery, whereby the developing fetus will 
be particularly prone to epigenetic errors due 
to epigenetic reprogramming shortly after 
implantation and/or the high rate of DNA 
synthesis. In addition, blood lead has been 
shown to influence homocysteine levels, 
which is associated with reductions in DNA 
methylation (Yi et al. 2000), likely through 
inhibition of DNA methyltransferases (Cox 
et al. 1977; James et al. 2002).
The large differences in Alu and LINE-1 
methylation levels (26% and 79%, respectively) 
are assay dependent, because both elements are 
known to be heavily methylated in normal 
tissue. The Alu assay, designed based on its 
consensus sequence, has undergone extensive 
C-to-T transitions, thereby limiting the pool of 
CpG sites to be methylated (Yang et al. 2004). 
The LINE-1 assay, however, targets the pro-
moter region, which is largely 5´-truncated in 
most LINE-1 elements except those thought to 
be of more recent evolutionary origin (Estecio 
et al. 2007; Kazazian 2004).
Given that repeated measures are col-
lected within individuals (at the various CpG 
cites), we employed mixed effects models as 
the analysis tool to account for correlation 
structure of the data. This general approach 
has been previously used in analyses of DNA 
methylation (Tarantini et al. 2009). In those 
analyses and in ours, random effects for CpG 
site were used to model the average departure 
of each CpG site from the overall mean (bj). 
A random effect for this departure is appro-
priate because the actual departure perhaps 
holds little biological meaning (a well-defined 
biological interpretation could merit these 
differences be treated as fixed effects). One 
difference in our approach is that we used 
an unstructured covariance matrix to model 
the correlation structure within individuals as 
opposed to a compound symmetry assump-
tion (equivalent to using a random intercept 
for individual). Our data supported the use of 
an unstructured covariance both because the 
variance in percent methylation varied across 
sites, and the correlation between pairs of sites 
was not constant across different pairs of sites. 
Although the use of random intercepts for 
individuals lends itself to a nice interpreta-
tion (where the random intercept for person 
represents the individual’s deviation from the 
overall mean), the unstructured correlation 
assumption more closely described our data. 
The issue of selecting a correlation structure 
is relevant to obtain correct and most efficient 
standard errors for the regression coefficients, 
and is perhaps of more relevance for small 
samples. The need to model the correlation 
structures correctly can be easily relaxed by 
using robust standard errors.
A limitation to this study is the use of 
leuko  cyte DNA methylation levels as a proxy 
for lead-induced changes in epigenetic patterns 
in target tissue for lead toxicity. For example, 
no data exist regarding whether the extent of 
methylation levels within circulating DNA are 
representative to DNA methylation changes in 
other tissue such as the central nervous system. 
Furthermore, because leukocyte DNA is a mix 
of numerous cell types, we cannot rule out the 
possibility that lead may induce small shifts in 
white blood cell populations, which may have 
influenced our findings. An additional limita-
tion to this study is that the LINE-1 and Alu 
methylation data represent a weighted average 
of DNA methylation across the genome and 
does not represent absolute methylation levels, 
nor does it provide fine epigenomic mapping 
of DNA methylation patterns across specific 
chromosomal regions. Additional research 
is warranted to assess whether prenatal lead 
exposure influences epigenome-wide DNA 
methylation patterning as well as gene-specific 
DNA methylation profiles.
In conclusion, we found an inverse 
associa  tion between cumulative lead meas-
ures and genomic DNA methylation among 
newborn samples. Our results suggest that 
the epi  genome of the developing fetus can 
be influenced by maternal cumulative lead 
burdens, suggesting that the epigenome may 
be a likely target by which intergenerational 
transmission of lead burdens may influence 
long-term epigenetic programming, which in 
turn may affect disease susceptibility through-
out the life course.
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